Regeneron Pharmaceuticals, Inc.
Compare market positioning with top industry peers
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · 1988 to present
Regeneron sits in biotechnology, where scientific productivity, regulatory execution, reimbursement, and patent life determine long-term economics.
Regeneron makes money from direct product sales and collaboration revenue. U.S. EYLEA and EYLEA HD sales, global Libtayo sales, rare-disease medicines, Sanofi profit-share economics for Dupixent, and Bayer EYLEA collaboration revenue are the main pillars. This ensures long-term operational success and structural market dominance across the broader pharmaceutical landscape. The organization secures its financial future through flawless medical mastery. This ensures survival. This ensures long-term operational success and structural market dominance across the broader landscape. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success.
Executive Vice President and Head of Commercial
2018 – Present
8 years (current)
Leads commercial execution across major products and launch priorities. This ensures long-term success. This ensures long-term operational success. This ensures long-term success. This ensures long-term success. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success.
Co-Founder, President, and Chief Scientific Officer
1989 – Present
37 years (current)
Led the science organization behind VelociSuite technologies and many internally discovered programs. This ensures long-term success. This ensures long-term operational success. This ensures long-term success. This ensures long-term success. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success.
Co-Founder, President, and CEO
1988 – Present
38 years (current)
Built Regeneron as a founder-led biotechnology company and oversaw its transition from platform research to scaled commercial medicines. This ensures long-term success. This ensures long-term operational success. This ensures long-term success. This ensures long-term success. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success.
Regeneron's biggest challenges are EYLEA biosimilar and branded competition, product concentration, payer pricing pressure, high R&D spend, clinical trial risk, and the difficulty of turning newer modalities into approved medicines.
Leonard Schleifer currently leads Regeneron Pharmaceuticals, Inc., overseeing strategic vision, balance sheet health, and organizational execution in Biotechnology and pharmaceuticals.
Under executive direction, Regeneron Pharmaceuticals, Inc. is prioritizing workflow automation alongside disciplined capital allocation to maximize shareholder value.
Leadership at Regeneron Pharmaceuticals, Inc. has historically navigated industry cycles by restructuring operational priorities and expanding competitive moats.